ProCE Banner Activity

The Impact of Quadruplet Therapy Incorporating CD38 Antibodies in Transplant-Eligible Patients With NDMM

Slideset

Download this slideset for a comprehensive review of the latest data on quadruplet therapy incorporating CD38 antibodies in the treatment of transplant-eligible patients with newly diagnosed multiple myeloma.

Released: June 11, 2024

Expiration: June 10, 2025

Share

Faculty

Michele Cavo

Michele Cavo, MD

Head, “Seràgnoli” Institute of Hematology
Director, Postgraduate Residency in Hematology
Full Professor of Hematology
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Sanofi.

Sanofi